- Home
- IDR vs IVVD Comparison
IDR vs IVVD Comparison
Compare IDR & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IDR
- IVVD
- Stock Information
- Founded
- IDR 1996
- IVVD 2020
- Country
- IDR United States
- IVVD United States
- Employees
- IDR N/A
- IVVD N/A
- Industry
- IDR Precious Metals
- IVVD Biotechnology: Pharmaceutical Preparations
- Sector
- IDR Basic Materials
- IVVD Health Care
- Exchange
- IDR Nasdaq
- IVVD Nasdaq
- Market Cap
- IDR 154.1M
- IVVD 123.8M
- IPO Year
- IDR N/A
- IVVD 2021
- Fundamental
- Price
- IDR $14.31
- IVVD $0.61
- Analyst Decision
- IDR Strong Buy
- IVVD Strong Buy
- Analyst Count
- IDR 1
- IVVD 4
- Target Price
- IDR $14.00
- IVVD $7.89
- AVG Volume (30 Days)
- IDR 165.5K
- IVVD 2.6M
- Earning Date
- IDR 05-05-2025
- IVVD 03-20-2025
- Dividend Yield
- IDR N/A
- IVVD N/A
- EPS Growth
- IDR 344.26
- IVVD N/A
- EPS
- IDR 0.67
- IVVD N/A
- Revenue
- IDR $25,765,373.00
- IVVD $25,384,000.00
- Revenue This Year
- IDR $86.37
- IVVD $606.63
- Revenue Next Year
- IDR $11.11
- IVVD $120.93
- P/E Ratio
- IDR $21.37
- IVVD N/A
- Revenue Growth
- IDR 64.94
- IVVD N/A
- 52 Week Low
- IDR $7.59
- IVVD $0.36
- 52 Week High
- IDR $18.35
- IVVD $4.74
- Technical
- Relative Strength Index (RSI)
- IDR 62.44
- IVVD 36.43
- Support Level
- IDR $13.20
- IVVD $0.58
- Resistance Level
- IDR $14.22
- IVVD $0.68
- Average True Range (ATR)
- IDR 0.79
- IVVD 0.09
- MACD
- IDR 0.18
- IVVD -0.02
- Stochastic Oscillator
- IDR 97.19
- IVVD 8.97
About IDR Idaho Strategic Resources Inc.
Idaho Strategic Resources Inc is a vertically integrated, operating junior mining company. It produces gold at the Golden Chest Mine. In addition to gold and gold production, the company maintains a strategic and domestic presence in the Critical Minerals sector and is focused on advancing its officially recognized Lemhi Pass, Diamond Creek, and Roberts Rare Earth Element projects in central Idaho.
About IVVD Invivyd Inc.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.